Clinical Trial Detail

NCT ID NCT02546661
Title Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors AstraZeneca
Indications

invasive bladder transitional cell carcinoma

Therapies

AZD9150 + Durvalumab

Durvalumab + Selumetinib

AZD4547

Durvalumab + Olaparib

Durvalumab

AZD4547 + Durvalumab

Durvalumab + Vistusertib

Adavosertib + Durvalumab

Age Groups: adult senior

Additional content available in CKB BOOST